ArticleFrontiers in pharmacology2026
Profibrotic predictive toxicology in the lung.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibiotic-Induced Pulmonary Fibrosis: National Database Analysis.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Fibrosis in the gossamer alveolar capillary membranes of the lung can lead to abnormalities in gas exchange, hypoxemia and death of the individual. These interstitial lung diseases (ILDs) of known or yet undefined etiologies (such as Idiopathic pulmonary fibrosis) highlight the need for predictive, physiologically relevant models for toxicity studies. Three-dimensional (3D) lung organoids derived from animal cells provide an advanced platform that replicates the structural and cellular complexity of lung tissue while reducing whole-animal use. Methods: Mouse lung organoids (MiLO) were used to evaluate pulmonary toxicity caused by environmental toxicants and pharmacologic agents. MiLO were generated from perfused, minced mouse lungs that were digested with collagenase, filtered, depleted of red blood cells, and embedded in Matrigel. Organoids were stained for lineage markers to characterize cellular diversity, including SPC, α-SMA, CD31, F4/80 and ECM proteins collagen I and fibronectin. Gene expression in MiLO and native lung tissue was compared for fibrosis- and viability-related markers. A well-characterized mouse model of cadmium induced lung fibrosis was used as an in vivo benchmark to assess α-SMA expression, airway resistance to methacholine, hydroxyproline content, malondialdehyde levels (MDA), and superoxide dismutase (SOD) activity. For drug-induced fibrosis modeling, cell viability assays defined 20% inhibitory concentrations of nitrofurantoin (NF, 5 μM) and amiodarone (AD, 20 μM), which were then used to treat MiLO for assessment of MDA, invasion area on collagen-coated plates, and expression of fibrotic and signaling markers. Results: MiLOs faithfully recapitulated native lung architecture, extracellular matrix composition, and fibrosis-related gene expression profiles. In vivo cadmium exposure increased α-SMA expression, airway resistance, collagen content, and malondialdehyde (MDA) levels, while reducing superoxide dismutase (SOD) activity. Consistently, Cd- treated MiLOs exhibited increases in COL1A1 deposition, cellular invasion, hydroxyproline content, and oxidative stress. Exposure to nitrofurantoin (NF) or amiodarone (AD) elevated MDA, enhanced invasion, and upregulated fibrogenic and signaling genes including Tgfb1, Col1a1, Acta2, Akt1, Nfkb1, and Mmp9. Environmental toxicant (Cd) and drug (AD or NF) treatments drove the development of hallmark fibrotic features in lung organoids, characterized by increased collagen deposition, oxidative stress, and profibrotic gene activation. Conclusions: These findings demonstrate that mouse lung organoids effectively recapitulate key molecular and pathological aspects of drug- and toxin-induced pulmonary fibrosis and represent a powerful model for mechanistic investigation and preclinical screening of compounds with potential pro-fibrotic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.